HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the US1
The FDA's approval of Carbometyx was based on results from the CELESTIAL phase 3 pivotal trial of Carbometyx for patients with advanced HCC who received prior sorafenib. Carbometyx demonstrated a statistically significant and clinically meaningful improvement in overall survival versus placebo.
On November 15, 2018, Exelixis' partner Ipsen received approval from the European Commission for Carbometyx tablets as a monotherapy for HCC in adults who have previously been treated with sorafenib.
In the pivotal CELESTIAL trial, median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76, 95% CI 0.63-0.92; p=0.0049).
Median progression-free survival was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44, 95% CI 0.36-0.52; p
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886